Simponi Also Approved for Treatment of Ulcerative Colitis

by U.S. Medicine

July 5, 2013

HORSHAM, PA – A new treatment is available for adults with moderate to severe ulcerative colitis.

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection, which works by blocking tumor necrosis factor (TNF). Simponi is marketed by Janssen Biotech Inc.

Previously approved to treat rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Simponi is approved to treat adults with moderate to severe ulcerative colitis that is resistant to prior treatment or requires continuous steroid therapy.
Safety and effectiveness of Simponi used to treat ulcerative colitis were established in two clinical studies. Evaluations of patients included measures of stool frequency, rectal bleeding, endoscopic findings and a physician’s overall assessment.
The most common side effects in patients treated with Simponi are upper respiratory infection and redness at the site of injection. Patients treated with the drug are at increased risk of also developing serious infections, invasive fungal infections, reactivation of Hepatitis B infection, lymphoma, heart failure, nervous system disorders and allergic reactions.


Related Articles

EMR Alert Helps Reduce Opioid/Benzodiazepine Co-Prescribing Risk at VAMCs

Since the launch of the Opioid Safety Initiative in 2012, the VA has implemented a number of steps designed to reduce the use of opioids and the risk of addiction and overdose among veterans.

VA Takes the Lead to Prevent Spread of Multi Drug-Resistant Organisms

The VA is leveraging its position as the country’s largest integrated healthcare system to slow the development and spread of multidrug-resistant organisms (MDRO).


U.S. Medicine Recommends


More From pharmacy

Pharmacy

EMR Alert Helps Reduce Opioid/Benzodiazepine Co-Prescribing Risk at VAMCs

Since the launch of the Opioid Safety Initiative in 2012, the VA has implemented a number of steps designed to reduce the use of opioids and the risk of addiction and overdose among veterans.

Pharmacy

VA Takes the Lead to Prevent Spread of Multi Drug-Resistant Organisms

The VA is leveraging its position as the country’s largest integrated healthcare system to slow the development and spread of multidrug-resistant organisms (MDRO).

Pharmacy

Military E-Prescriptions Exceed 50% Goal Set Three Years Ago

FALLS CHURCH, VA — As of January 2018, 54% of prescriptions filled by MTFs were submitted electronically, exceeding the initial goal of 50% set when the e-prescribing program first rolled out three years ago.

Pharmacy

San Diego Revises Alert System in Wake of Administration of Compromised Flu Vaccine

In the fall, failure of a pharmacy refrigerator and its monitoring system resulted in 1,540 veterans and staff receiving potentially ineffective shots.

Pharmacy

Shortage of Supplies Might Have Delayed Medical Procedures at VAMCs

In response to complaints that clinicians at VAMCs lack adequate medical and surgical products to care for veterans, VA conceded it needs to make its product formulary more robust.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up